FDA Inspectors Increasing Scrutiny of Supplier Controls: Official

The GMP Letter
Amid continuing concern that breaks in the global supply chain will beget another heparin crisis, FDA inspectors are upping scrutiny of drug and device manufacturers’ supplier controls to ensure they are sufficiently robust and clearly articulated in scientific terms, agency officials say.

To View This Article:


Subscribe To The GMP Letter

Buy This Article Now

Add this article to your cart for $40.00